Core Viewpoint - Shanghai Haili Biological Technology Co., Ltd. announced that its subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the registration application of three types of medical devices, specifically "bone repair materials" [1] Group 1: Product Details - The products are classified as Class III medical devices, suitable for filling and repairing maxillofacial bone defects and alveolar bone defects (or insufficient bone volume) [1] - The application includes structured products such as block and column types, which can better match the bone defect areas compared to the existing granular bone repair materials, effectively reducing bone powder displacement and improving surgical efficiency and osteogenic effects [1] Group 2: Regulatory Process - The registration application is currently in the review and approval stage, with a statutory administrative approval period of 20 working days, which can be extended by an additional 10 working days under special circumstances [1] Group 3: Market Implications - If the product is successfully approved for market launch, it will enrich Haili Biological's product line in the field of oral bone defect repair [1] - The company notes that the product is still in the acceptance stage, and its impact on future performance remains uncertain [1]

Core Viewpoint - Haili Biological (603718.SH) announced that its subsidiary, Shaanxi Ruisheng Biotechnology Co., Ltd., has received a medical device registration application acceptance notice from the National Medical Products Administration for a bone repair material [1] Company Summary - The product, classified as a Class III medical device, falls under the category of oral medical devices, specifically "17-08 Oral Implant and Tissue Reconstruction Materials" and "17-08-06 Bone Filling and Repair Materials" [1] - The product classification code is 17-08-06, indicating its specific use in the dental field [1] - Once approved for market launch, this product will enhance Ruisheng Biological's product line in the field of oral bone defect repair [1] Industry Summary - The approval of this bone repair material aligns with the growing demand for advanced medical devices in the dental sector, particularly for bone repair solutions [1] - The classification as a Class III medical device suggests a significant level of regulatory scrutiny, indicating the product's potential impact on patient care and safety in oral surgery [1]

证券代码：603718 证券简称：海利生物 公告编号：2025－038 上海海利生物技术股份有限公司 关于控股子公司三类医疗器械注册申请获得受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海海利生物技术股份有限公司（以下简称"公司"）控股子公司陕西瑞盛生物 科技有限公司（以下简称"瑞盛生物"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）下发的医疗器械注册申请受理通知信息，现将相关情况公告如下： 一、该医疗器械的基本信息 申请人：陕西瑞盛生物科技有限公司 产品名称：骨修复材料 临床用途：适用于颌面骨缺损、牙槽骨缺损（或骨量不足）填充和修复 该医疗器械目前注册申请已获得受理。 三、 后续所需审批流程 后续所需的审批流程：审评审批、制证。 办结时限：行政审批 20 个工作日，特殊情况延长 10 个工作日。检验检测，技术 审评等不计入法定审批时限。 四、产品相关情况 口腔科骨缺损修复手术主要针对牙槽骨缺损或吸收导致的功能与美观问题，常见 于牙周炎、外伤或种植牙术前骨量不足。手术通过植入骨修复材料（如自体 ...

Core Viewpoint - The announcement indicates that the application for the registration of bone repair materials by Shaanxi Ruisheng Biotechnology Co., Ltd. has been accepted by the National Medical Products Administration, which is a significant step for the company in expanding its product line in the dental field [1] Group 1 - The bone repair material is designed for filling and repairing maxillofacial bone defects and alveolar bone deficiencies, making it a critical material for oral surgery [1] - The new product will supplement the existing bone repair materials offered by Ruisheng Biotechnology, thereby enriching its product portfolio [1] - Currently, the product is in the acceptance stage, and it is expected that there will be no definitive impact on the company's existing business and operating performance [1]

Market Overview - The animal health sector increased by 1.34% on September 1, with Jinhe Biology leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Stock Performance - Jinhe Biology (002688) closed at 7.53, up 6.06% with a trading volume of 875,700 shares and a turnover of 651 million yuan [1] - Other notable performers included *ST Lvkang (002868) with a 5.02% increase, and Shunlian Biology (688098) with a 1.78% increase [1] - The overall trading data for the animal health sector is summarized in the provided table [1] Capital Flow - The animal health sector saw a net inflow of 26.58 million yuan from institutional investors, while retail investors experienced a net outflow of 7.06 million yuan [2] - The detailed capital flow for individual stocks indicates varying levels of institutional and retail participation [3] Individual Stock Analysis - Jinhe Biology had a net inflow of 88.59 million yuan from institutional investors, while retail investors showed a net outflow of 37.91 million yuan [3] - Other stocks like Kexin Biology (688526) and *ST Lvkang (002868) also experienced mixed capital flows, with significant retail outflows [3]

Market Overview - As of 10:29 AM today, the Shanghai Composite Index stands at 3864.71 points, above the annual line, with a change of 0.18% [1] - The total trading volume of A-shares today is 138.21 billion yuan [1] Stocks Breaking Annual Line - A total of 41 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Energy Iron Han (节能铁汉) with a deviation rate of 14.24% and a daily increase of 14.69% [1] - Qidi Environment (启迪环境) with a deviation rate of 7.10% and a daily increase of 10.26% [1] - ST Quanwei (ST泉为) with a deviation rate of 6.60% and a daily increase of 9.06% [1] Detailed Stock Performance - The following table summarizes the performance of selected stocks that have recently broken the annual line: | Stock Code | Stock Name | Daily Change (%) | Turnover Rate (%) | Annual Line (yuan) | Latest Price (yuan) | Deviation Rate (%) | | --- | --- | --- | --- | --- | --- | --- | | 300197 | 节能铁汉 | 14.69 | 5.66 | 2.12 | 2.42 | 14.24 | | 000826 | 启迪环境 | 10.26 | 8.19 | 2.01 | 2.15 | 7.10 | | 300716 | ST泉为 | 9.06 | 3.95 | 10.05 | 10.71 | 6.60 | | 001215 | 千味央厨 | 3.57 | 2.39 | 29.19 | 30.19 | 3.43 | | 601882 | 海天精工 | 5.10 | 1.67 | 20.52 | 21.02 | 2.45 | | 601298 | 青岛港 | 2.59 | 0.45 | 8.54 | 8.72 | 2.09 | | 002771 | 真视通 | 3.22 | 3.18 | 17.64 | 17.97 | 1.85 | | 600653 | 申华控股 | 2.56 | 1.44 | 1.97 | 2.00 | 1.76 | | 300141 | 和顺电气 | 1.77 | 1.04 | 9.07 | 9.22 | 1.63 | | 002390 | 信邦制药 | 2.75 | 1.17 | 3.68 | 3.73 | 1.46 | | 600189 | 泉阳泉 | 1.49 | 1.23 | 7.38 | 7.48 | 1.41 | | 601328 | 交通银行 | 1.51 | 0.53 | 7.28 | 7.38 | 1.40 | | 600518 | 康美药业 | 4.41 | 2.72 | 2.10 | 2.13 | 1.25 | | 300318 | 博晖创新 | 1.18 | 0.45 | 5.92 | 5.98 | 1.08 | | 300144 | 宋城演艺 | 1.49 | 1.35 | 8.82 | 8.88 | 0.72 | | 600916 | 中国黄金 | 1.83 | 2.15 | 8.27 | 8.33 | 0.71 | | 300067 | 安诺其 | 1.48 | 1.87 | 5.44 | 5.47 | 0.61 | | 600272 | 开开实业 | 1.36 | 1.09 | 13.39 | 13.45 | 0.48 | | 603310 | 巍华新材 | 0.61 | 0.69 | 17.96 | 18.05 | 0.47 | | 603718 | 海利生物 | 0.70 | 0.66 | 7.17 | 7.20 | 0.41 | | 603768 | 常青股份 | 0.95 | 0.80 | 12.72 | 12.76 | 0.35 | | 600062 | 华润双鹤 | 1.08 | 0.71 | 19.60 | 19.66 | 0.30 | | 300784 | 利安科技 | 2.40 | 3.84 | 56.62 | 56.78 | 0.29 | | 600236 | 桂冠电力 | 0.32 | 0.05 | 6.32 | 6.34 | 0.28 | | 300076 | GQY视讯 | 1.71 | 1.47 | 6.54 | 6.56 | 0.25 | | 601898 | 中煤能源 | 0.97 | 0.11 | 11.42 | 11.45 | 0.24 | [1]

Market Overview - The animal health sector experienced a decline of 0.5% on August 29, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Individual Stock Performance - The top performer in the animal health sector was Qudongli (code: 838275), with a closing price of 11.87 and an increase of 7.23% [1] - Other notable gainers included Yongshun Biological (code: 839729) with a 1.34% increase and Ruipu Biological (code: 300119) with a 0.81% increase [1] - Conversely, *ST Lvkang (code: 002868) saw a significant decline of 3.24%, closing at 26.32 [2] Trading Volume and Capital Flow - The total net outflow of main funds in the animal health sector was 53.36 million yuan, while retail funds saw a net inflow of 29.48 million yuan [2] - The trading volume for Qudongli was 92,700 hands, with a transaction amount of 108 million yuan [1] Fund Flow Analysis - *ST Lvkang experienced a net outflow of 11.85 million yuan from main funds, representing a 24.27% net share [3] - In contrast, retail funds for *ST Lvkang saw a net inflow of 7.44 million yuan, accounting for 15.25% of its total [3] - Other companies like Shenglian Biological and Zhongmu Co. also faced net outflows from main funds, indicating a trend of capital withdrawal in the sector [3]

据证券之星公开数据整理，近期海利生物(603718)发布2025年中报。截至本报告期末，公司营业总收入 1.1亿元，同比上升2.02%，归母净利润1823.48万元，同比上升20.56%。按单季度数据看，第二季度营 业总收入4798.39万元，同比上升28.66%，第二季度归母净利润733.31万元，同比下降61.09%。本报告 期海利生物盈利能力上升，毛利率同比增幅61.39%，净利率同比增幅202.08%。 本次财报公布的各项数据指标表现尚佳。其中，毛利率77.11%，同比增61.39%，净利率29.13%，同比 增202.08%，销售费用、管理费用、财务费用总计3773.23万元，三费占营收比34.37%，同比减41.85%， 每股净资产2.41元，同比增26.35%，每股经营性现金流0.06元，同比增227.86%，每股收益0.03元，同比 增20.51% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 1.08亿 | 1.1亿 | 2.02% | | 归母净利润（元） | 1512.5万 | 1823. ...

Market Overview - The animal health sector experienced a decline of 1.01% on August 28, with *ST Lvkang leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.07, up 5.23% [1] - Xianfeng Holdings (002141) at 4.19, up 1.21% [1] - Zhongmu Co. (600195) at 7.63, up 0.66% [1] - Major decliners included: - *ST Lvkang (002868) at 27.20, down 3.51% [2] - Shenyuan Bio (688098) at 12.59, down 2.70% [2] - KQ Bio (688526) at 18.40, down 1.55% [2] Capital Flow - The animal health sector saw a net outflow of 136 million yuan from institutional investors, while retail investors contributed a net inflow of 101 million yuan [2] - The detailed capital flow for key stocks showed: - Zhongmu Co. had a net outflow of 18.59 million yuan from institutional investors [3] - *ST Lvkang experienced a significant net outflow of 7.31 million yuan from institutional investors [3] - Retail investors showed a net inflow of 5.64 million yuan into *ST Lvkang [3]

Group 1 - Company reported a total revenue of 110 million yuan, ranking 9th among disclosed peers [1] - The net profit attributable to shareholders was 18.23 million yuan, also ranking 9th among disclosed peers [1] - The net cash inflow from operating activities was 38.12 million yuan, ranking 7th among disclosed peers [1] Group 2 - The latest debt-to-asset ratio is 5.51% [3] - The latest gross profit margin is 77.11% [3] - The latest return on equity (ROE) is 1.15%, ranking 8th among disclosed peers, a decrease of 0.05 percentage points compared to the same period last year [3] Group 3 - The diluted earnings per share is 0.03 yuan, ranking 9th among disclosed peers [4] - The latest total asset turnover ratio is 0.06 times, ranking 11th among disclosed peers, a decrease of 0.01 times, representing a year-on-year decline of 9.39% [4] - The latest inventory turnover ratio is 0.43 times, ranking 11th among disclosed peers, a decrease of 0.12 times, representing a year-on-year decline of 21.24% [4] Group 4 - The number of shareholders is 31,600, with the top ten shareholders holding 329 million shares, accounting for 50.20% of the total share capital [4] - The largest shareholder is Shanghai Haoyuan Venture Capital Development Co., Ltd., holding 34.50% [4]